预约演示
更新于：2026-07-28
Adebrelimab
阿得贝利单抗
更新于：2026-07-28
概要
基本信息
原研机构 |
在研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2023-02-28), |
最高研发阶段(中国)批准上市 |
特殊审评特殊审批 (中国)、突破性疗法 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 13388064H
来源: *****
Sequence Code 13388069L
来源: *****
关联
435
项与 阿得贝利单抗 相关的临床试验NCT07704645
A Phase II Clinical Study of Adebelizumab Combined With Other Anti-tumor Treatments as a Perioperative Treatment for Resectable Non-small Cell Lung Cancer
NCT07684040
A Prospective Single-arm Clinical Study Evaluating the Efficacy and Safety of Hepatic Resection After Initial Hepatic Arterial Infusion Chemotherapy Combined With Adebrelimab Plus Rivoceranib in Patients With Initially Resectable Hepatocellular Carcinoma
NCT07583550
Efficacy and Safety of Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy and Sequential Adebrelimab Maintenance Therapy for Extensive-stage Small Cell Lung Cancer: A Prospective, Multicenter Phase II Study
100 项与 阿得贝利单抗 相关的临床结果
登录后查看更多信息
100 项与 阿得贝利单抗 相关的转化医学
登录后查看更多信息
100 项与 阿得贝利单抗 相关的专利（医药）
登录后查看更多信息
46
项与 阿得贝利单抗 相关的文献（医药）2026-06-01Therapeutic Advances in Medical Oncology
Adebrelimab-based regimens as first-line treatment for ES-SCLC in specific populations: a real-world study in Chinese patients
Article
作者: Zhai, Nailiang ; Peng, Jianfeng ; Jiang, Liyang ; Meng, Xiangjiao ; Shao, Zhenyu ; Wen, Junxu ; Xu, Shuangbing ; Meng, Ling ; Kong, Lingling ; Huang, Zhaoqin ; Wu, Peizhu ; Zhao, Kaikai
Background::
The efficacy and safety of adebrelimab plus carboplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) have been investigated in the CAPSTONE-1 study. However, many patients with brain metastases, as well as some with liver metastases and pleural effusion, were excluded.
Objectives::
The present study focuses on exploring the safety and efficacy of adebrelimab in these patients in the real world.
Design::
This was a multicenter, prospective, observational, real-world study.
Methods::
Patients with ES-SCLC and brain metastases, liver metastases, or pleural effusion who were willing to receive adebrelimab-based regimens as first-line therapy were enrolled. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate, disease control rate, duration of response, overall survival (OS), and safety.
Results::
Between March 2, 2023, and September 3, 2024, a total of 149 patients were enrolled in the present study. Among them, 50 (33.6%) patients had brain metastasis, 60 (40.3%) had liver metastasis, and 85 (57.0%) had pleural effusion. At data cutoff (May 5, 2025), the median PFS (mPFS) was 6.47 months (95% confidence interval (CI): 5.85–7.03), and the median OS (mOS) was 13.77 months (95%CI: 11.30–15.44) in the full analysis set. Additionally, the mPFS were 6.01 months (95%CI: 4.83–7.59), 5.45 months (95%CI: 4.30–6.51 months), and 6.60 months (95%CI: 5.29–7.59 months) in patients with brain metastases, liver metastases, and pleural effusion, respectively. The mOS were 13.77 months (95%CI: 9.67–22.90 months), 10.51 months (95%CI: 8.38–13.44 months), and 12.85 months (95%CI: 9.20–16.39 months) in patients with brain metastases, liver metastases, and pleural effusion, respectively. Grade ⩾3 treatment-emergent adverse events occurred in 63 (42.3%) patients. No new safety signals were found.
Conclusion::
Adebrelimab-based regimens showed effectiveness comparable to clinical trials in special populations such as patients with brain metastases or pleural effusion, and demonstrated an acceptable safety profile. However, the benefit appeared limited in patients with liver metastases.
2026-05-01International Journal of Surgery
Adebrelimab in combination with dalpiciclib and endocrine therapy as neoadjuvant treatment for HR+/HER2− early breast cancer: an exploratory study
Article
作者: Ren, He ; Xiao, Min ; Liu, Tong ; Lei, Bo ; Wang, Jinsong ; Han, Xinhao ; Zhang, Crystal Song ; Huang, Fanxuan
Background::
Hormone receptor–positive (HR
+
)/HER2
−
breast cancer (BC) exhibits limited sensitivity to neoadjuvant chemotherapy, with low pathologic complete response (pCR) rates. While CDK4/6 inhibitors (CDK 4/6i) combined with endocrine therapy have demonstrated efficacy, the immunogenicity of HR
+
/HER2
−
tumors remains low, limiting the benefit of immunotherapy. Emerging evidence suggests potential synergy between CDK4/6 inhibition and immune checkpoint blockade. This study explores the neoadjuvant combination of adebrelimab, dalpiciclib, and endocrine therapy in patients with stage II–III HR
+
/HER2
−
BC.
Methods::
This single-arm, exploratory study enrolled postmenopausal women with histologically confirmed stage II–III HR
+
/HER2
−
BC. Eligible patients received neoadjuvant therapy comprising adebrelimab (1200 mg intravenously, day 1), dalpiciclib (125 mg orally, once daily on days 1–21), and letrozole. Treatment was administered over five 28-day cycles prior to surgery. The primary endpoint was total pCR (tpCR; defined as ypT0-is/ypN0).
Results::
Between October 2024 and March 2025 patients (median age 61.5 years) with stage II–III HR
+
/HER2
−
BC were enrolled. Most patients had T2 tumors (85%) and N1 disease (55%). All patients received ≥1 treatment cycle; 17 completed surgery. Radiological partial response was observed in 13 patients (65%), with an overall objective response rate (ORR) of 65%. One patient (5%) achieved tpCR. Three patients discontinued due to adverse events (AE; one death, one hepatitis, and one pneumonia). Common grade ≥ 3 AEs included neutropenia (50%), leukopenia (25%), and elevated liver enzymes.
Conclusion::
This triplet regimen demonstrated modest clinical activity in HR
+
/HER2
−
early BC, with the safety profile of this regimen remains a concern and warrants particular attention in clinical practice.
2026-04-30CURRENT MEDICINAL CHEMISTRY
Apatinib and Adebrelimab Exhibit Synergistic Antitumor effects in
Small Cell Lung Cancer: An In Vitro Study
Article
作者: Huang, Laiquan ; Wu, Linfeng ; Wang, Yifan ; Cheng, Xiangwei ; Zhu, Yiping
Background::
Small cell lung cancer (SCLC) is a highly aggressive malignancy.
This study investigated whether Apatinib (Apa) combined with Adebrelimab (Ade)
exerted synergistic effects against SCLC.
Methods::
Half-maximal inhibitory concentration (IC50) value of Apa and Ade, administered
alone or in combination, was determined in H446 and H1436 cells using cell counting
kit-8 (CCK-8) assays. Synergistic effects were quantified by calculating fractional inhibitory
concentration (FIC) indices. Cell proliferation, migration, and invasion were assessed
by CCK-8, wound healing, and Transwell assays, respectively. After co-culture
with CD8+ T cells, PD-L1 expression and CD8+ IFN-γ+ T cell proportion were measured
by flow cytometry. TGF-β secretion and LDH release were detected using ELISA
and LDH assay, respectively; the protein level of VEGFR2 and STAT3 was analyzed by
western blot.
Results::
Apa alone exhibited IC50 values of 20.03 μM (H446) and 35.50 μM (H1436),
while Ade alone exhibited 5.789 μM and 6.959 μM, respectively. The sum FIC values
were 0.681 for H446 cells and 0.973 for H1436 cells. Compared with either monotherapy,
combined treatment more effectively reduced cell viability, migration, and invasion.
In co-culture experiments, the combination further suppressed PD-L1 expression and
TGF-β secretion, increased CD8+ IFN-γ+ T cells and LDH release, and downregulated
VEGFR2, p-STAT3, and PD-L1 protein levels.
Discussion::
This study demonstrated that the combination of Apa and Ade exerted synergistic
anti-tumor effects against SCLC in vitro. Further investigation, including animal
studies and clinical trials, is warranted to evaluate the efficacy and long-term safety of
this combination therapy.
Conclusion::
In summary, the combination of Apa and Ade represented a promising innovative
therapeutic strategy for SCLC.
100 项与 阿得贝利单抗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非小细胞肺癌 | 中国 | 2026-06-23 | |
| 广泛期小细胞肺癌 | 中国 | 2023-02-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 胃食管交界处腺癌 | 临床3期 | 中国 | 2026-05-07 | |
| 胃食管交界处腺癌 | 临床3期 | 中国 | 2026-05-07 | |
| 胃食管交界处癌 | 临床3期 | 中国 | 2026-05-07 | |
| 胃食管交界处癌 | 临床3期 | 中国 | 2026-05-07 | |
| 局部晚期直肠癌 | 临床3期 | 中国 | 2026-03-23 | |
| 晚期胆道癌 | 临床3期 | 中国 | 2026-01-21 | |
| 晚期宫颈癌 | 临床3期 | 中国 | 2025-10-08 | |
| 局部晚期宫颈癌 | 临床3期 | 中国 | 2025-10-08 | |
| PD-L1阳性三阴性乳腺癌 | 临床3期 | 中国 | 2025-08-20 | |
| 转移性胃食管结合部腺癌 | 临床3期 | 中国 | 2025-08-18 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 胸腺癌 一线 | 37 | (Advanced or recurrent thymic carcinoma) | 鹹膚鬱鬱艱膚廠鑰窪蓋(遞繭蓋餘鏇鹽鏇憲夢鑰) = 獵膚鏇範艱積顧製繭糧 網鬱憲鬱淵製鏇餘餘範 (廠壓顧遞膚醖觸網廠選 ) 更多 | 积极 | 2026-05-29 | |
临床2期 | 口腔鳞状细胞癌 新辅助 | 25 | Adebrelimab 1200 mg + cisplatin 75 mg/m2/docetaxel 75 mg/m2 | 淵醖網願齋簾齋鹽鏇願(構衊夢蓋鹽糧鑰選齋鏇) = 餘糧淵壓艱範壓範製鬱 鑰壓遞窪襯夢鹹蓋網簾 (淵顧廠積膚鑰鏇艱壓願 ) 更多 | 积极 | 2026-05-29 | |
Adebrelimab 1200 mg + cisplatin 75 mg/m2/docetaxel 75 mg/m2 (cT4b) | 淵醖網願齋簾齋鹽鏇願(構衊夢蓋鹽糧鑰選齋鏇) = 夢構夢製鹹鹽鹹鏇觸憲 鑰壓遞窪襯夢鹹蓋網簾 (淵顧廠積膚鑰鏇艱壓願 ) 更多 | ||||||
临床2期 | 局部晚期食管鳞状细胞癌 新辅助 | 43 | 艱鏇簾餘壓襯膚糧淵繭(鑰艱憲衊簾窪簾憲範範) = 鹹遞鬱鹽選遞醖醖鏇蓋 壓網遞醖餘壓憲觸壓鹽 (製蓋範膚醖糧衊獵夢夢 ) 更多 | 积极 | 2026-05-29 | ||
临床1期 | 胰腺导管腺癌 辅助 | 16 | 糧膚積鹽範願壓築網繭(廠繭獵齋觸衊蓋衊鏇餘) = 鬱繭構範願繭繭艱製觸 壓鹽遞壓醖鑰鏇鬱鹽壓 (憲廠繭簾鑰鏇醖廠鏇網 ) 更多 | 积极 | 2026-05-29 | ||
临床1/2期 | 15 | 襯觸選衊糧鹹獵鏇鏇壓(獵顧襯窪願壓襯選蓋選) = 艱築築築壓艱製齋鑰淵 艱鹽築鏇醖構膚範鏇壓 (齋鬱積鏇觸膚繭糧蓋鹽 ) | 积极 | 2026-05-29 | |||
Adebrelimab 20 mg/kg or 1200 mg | 襯觸選衊糧鹹獵鏇鏇壓(獵顧襯窪願壓襯選蓋選) = 淵顧鬱壓鬱鏇醖構淵鑰 艱鹽築鏇醖構膚範鏇壓 (齋鬱積鏇觸膚繭糧蓋鹽 ) | ||||||
临床2期 | 可切除非小细胞肺癌 新辅助 | 37 | 糧獵願憲鏇築衊艱遞艱(遞鬱積鬱鏇夢築膚鏇網) = 蓋構範壓顧鏇築簾築淵 壓鹽蓋網夢鏇網網淵鏇 (窪構壓夢構衊壓糧簾廠 ) 更多 | 积极 | 2026-05-29 | ||
临床2期 | 肿瘤 一线 | 29 | 夢醖廠齋廠衊壓壓膚壓(艱淵遞鹽積壓餘觸簾願) = 鹹繭齋憲願選夢齋繭簾 夢製顧淵廠鹹鬱築鹽醖 (艱淵蓋夢製顧簾鑰構艱 ) 更多 | 积极 | 2026-05-29 | ||
临床2期 | 不可切除的肝内胆管癌 新辅助 | 31 | 鹹願構醖範齋築築醖築(鹽獵夢簾憲網構壓膚鹽) = 鏇簾鑰衊選鏇網繭糧範 憲簾願膚鹹壓觸製獵鬱 (窪鏇繭醖製觸衊範糧糧 ) 更多 | 积极 | 2026-05-29 | ||
临床1/2期 | 转移性胰腺癌 一线 | 28 | 窪憲築蓋廠遞簾願鏇襯(齋壓夢鹽糧憲醖齋積願) = 積繭鑰繭積餘鏇範選簾 鑰選衊鹽糧獵艱窪齋醖 (憲觸製遞憲範襯願醖遞 ) 更多 | 积极 | 2026-05-29 | ||
临床2期 | 结直肠癌肝转移 Microsatellite stable (MSS) | 45 | Adebelimab + stratified targeted therapy + liposomal irinotecan-based chemotherapy | 簾遞簾鑰範衊鏇製範衊(鏇獵繭選範糧壓鏇鹹觸) = 憲簾衊醖餘遞壓淵淵鹽 觸鹽鹹窪顧蓋醖憲簾餘 (鬱積衊艱窪願顧獵衊糧, 27.3 ~ 60.0) 更多 | 积极 | 2026-05-29 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用